Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 11/20 | 0.42 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186309 | 0.82 | NMBR (0.51) | NMBRSOAT2SOAT1 | |
| SCHEMBL6799588 | 0.82 | NMBR (0.45) | NMBRSOAT2SOAT1 | |
| SCHEMBL6803553 | 0.81 | NMBR (0.50) | NMBRSOAT2SOAT1 | |
| SCHEMBL6804233 | 0.80 | NMBR (0.52) | NMBRSOAT2SOAT1 | |
| SCHEMBL6805340 | 0.80 | NMBR (0.48) | NMBRSOAT2SOAT1 | |
| SCHEMBL6182338 | 0.78 | NMBR (0.47) | NMBRSOAT2SOAT1 | |
| SCHEMBL6218992 | 0.77 | NMBR (0.46) | NMBRSOAT2SOAT1 | |
| SCHEMBL6185673 | 0.77 | NMBR (0.45) | NMBRSOAT2SOAT1MEN1KMT2A | |
| SCHEMBL6808025 | 0.76 | NMBR (0.44) | NMBRSOAT2SOAT1 | |
| SCHEMBL6183034 | 0.76 | NMBR (0.48) | NMBRSOAT2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | NMBR 211/4885SOAT2 3379/4885SOAT1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.